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A TYPI CAL OHOLINES!ERASE 
At least two distinct torms of cholinesterase exist 
within the bodl'. Oho11nesterase Il, also known as specific; 
cho11nesterase, true- cholinesterase, E-type; cholinesterase, 
and acetyl cholinesterase is present in red cells and ner-
vous tissue. I.ts function is poorly understood but it 
apparently has both muscarinic and nicotinic functions') in 
neurohumoral transmission~IOholinesterase II, also known 
as atypical cholinesterase, nonspecific cholinesterase, 
pseudocholinesterase, S-type cholinesterase, and acyl-choline-
acyl-hydrolase, is synthesized in liver and is present in 
plasma and many other tissues?' 
The estimation of plasma cholinesterases mal' have clin-
ioal value in such conditions as liver amldb11I6,rl' tract 
diseases, malnutrition, fluorophospbate ester pOison1ng and 
1n patients being treated w1th thio-TEPA for cancer. Plasma 
oholinesterase levels may also be reduced atter ingestion of 
such drugs as chlorpromaz1ne, morphine, estrogens, cortisone1 
quinine, prost1gmln, physostigmIne. and procalne.2~ 
a.rum cholinesterase hydrolyzes succ1nylchollne,;as 1t 
does prooaine and other eS,ters of benzoic acid. In1 t1all7, it 
istranstormed to succ1n,I monocholine and cho11ne. Sllcc1nyl 
monochollne, a weak neuromuscular blocker about 1/20 as 
potent as succ1nylchol1ne, 1s in turn hydrolyzed to succ1n1nc 
aoid and choline. Under ph;rsiolog10 conditions the tirst reaotion 
o~curssix times more rapidly than the second. Serum cho-
linesterase acts only wbilee sJlccinylcholine is present in 
the blood. Enzymatic activity increases with a rising con-
centration of the drugs. fhe rate of hydrolyses is rapid, 
about 90% of the injected dose is destroyed in the first 
minute; heme enzyme activity is of importance only briefly 
but serves to limit the amount of relaxant that reaches .. ttle 
neuromuscular end-plate. T.rminatlon of aotion is probably 
caused by diffusion from ttle end-plate into the interstitial 
fluid. 
It has been noted that oertain individuals given succinyl-
oholine undergo profound protracted apnea responsive only to 
assisted ventilation. In these cases, known as "suxamethonlumit'lpneaM, 
the plasma pseudocholinesterase levels were found to be lower 
than normal. It was noted that they aalso demonstrated Invitro 
reststance to enzymatic inhibition by such compounds as dibu-
caine, fluorlie:and If-butanol. This inhibition was not present 
in patients lacking this susceptibility to succinylcholine):.4,6 
The need for determination of this plasma enzyme prior to ad-
ministration of suoh anesthetic agents is aovious. 
Genetic studies in families exhibiting this peouliarity 
in the pseudocholinesterase system revealed that the plasma 
levels tended to cluster in at least three areas. I~ has sub-
sequently been olarified that the genes for the first found 
loci of pseudocholinesterase (represented by El ) are probably 
alleles of the same locus. By describing the patients as E1
U 
(usual), I la (atyp1cal), Ils (s11ent), and :&:1t1- (fluoride,) 
ten geno*1pes bave been described. A patient wbo i8 homozygous 
for Bill 1s usual or normal and will show sat1sfactory inhi-
bition of serum cholinesterase by dibucaine, tluoride and 
B-butanol. Those who are homozygous .. tor Ii' are atypical and dtt 
not show satisfactory invitro inhibit10n of tne1r cholinesterase 
level. Tnese patients are detini**iy at r1sk to develop euxa-
methonium apnea although the attack rate is not 100% and is 
somewhat dose related. The absence of plasma pseudocholinesterase 
(homozygous I I S ) demonstrates the so-called silent gene in 
whicn no pseudocholinesterase activity is demonstrated in 
plasma. These cases are extremely rare.} 
H.tero~ygotes, that is combinations of Bl U and Ila show 
partial invitro ~nhibition but .t~ not to the degree of the 
true atypicals. These patients are apparently not att risk to 
develop suxamethonium apnea. 
N~rmall1 apprOXimately 80% of the pseudocholinesterase 
activity in plasma can be inhib1ted invitro by posit1vely 
charged quaternary n1trogen conta1ning molecules such as d1-
buca1ne. The per cent 1nh1b1t1on is inown as the dibucaine 
number. Surveys of the general papule. tion reveal that 94% of 
people tested show about 80% inhibition of their pseudo-
cholinesterase level by dibucaine and can be classified as 
homozygous for Bl~. Approx1mately ,_ will show 4G-60_ inhi-
-4-
b1t1on and ar. apparently heteroSTgotes show1ng a comb1nat1on 
of El
U and Ila or El
fl
• only 1 1n 4,000 pat1ents will show 
only 20% 1nvitro 1nhibit1on by dibucaine, are homozygous for 
I I
a
, and are definitely at risk for suxamethonium apnea. The" 
negatively charged fluoride ion may also be used as an invitro 
inhibitor: This inhibition 1s 1mmediate, constant, and rever-
sible, as studied by dialysis and dilution techniques. It is 
presumably a direct effect by the fluoride ion and not by com-
plexing with such metals as megnesium and calc1um or phospahte. 
The relit10nsh1p of the fluoride and d1bucaine inh1bition 
in heterozygotes has not been clearly established. It is 
possible that they are biochem1cal facets representing the 
same gene. However, studies of inhibitions by these two com-
pounds have shown that in neter,zygotes (11&. E1U).the inhi-
bition is relatively less by fluoride than by d1bucaine.1 
!boe neutral compound .~bu~nol has also beea used as an inh1-
bitor1 In all cases the atypical homozygotes as well as the 
usual homo zygotes are clearly defined. Unfortunately the 
def1nition of the het~ygotic phenotypes is not always 
clear nor separable depending on the inhibitor uaed.6 
Laboratory methods for quantitating the amount of cho-
linesterase present 1n plasma measure enzyme activ1ty and do 
4-
not d1fferentiate between the normal and atypical variety. 
Thus low enzyme levels may mean reduced amount of normal 
-5-
enz;yme~or the presence of the atypical enz;yme in varying 
amounts. 
~ny substrates have been util1zed for the determination 
of plasma true and pseudocholinesterases. Trlbytyr1n, acetyl-
beta-methylcho.11ne, benzoylcho11ne, phenylacetylcho11ne, and 
acetylcholine have all been used. At that the cholinesterases 
are relatively nonspec1fic and both also hydrol1ze a variety 
of noncholine esters. Substrate$specificit7 has been poorly 
defined but it is fairly well established that red cell true 
cholinesterase will hydrolyze acetyl-beta-methylcholine but 
not benzoylcholine, while the plasma pse.udochol1nesterase 
will react in Just the opposite faSb.1on~' 
The cases which were studies 1n this paper underwent 
varying degrees of suxamethonium apnea after administration 
of succinylcholine. Tb.e pseudocholinesterase activity in 
plasma of these individuals as well as members of their 
tamilies was determined by the method to be described.Por 
controls, approximately 30 normal individuals were tested 
utilizing the same procedure. 
Method 
The method for determination of atypical forms of pseudo-
cholinesterase used in this study was that of Kalow and 
Genest."Oholinesterase activity was determined by ultra-
violet spectropb.otometry at 240 nanometers using 5XIO-5 K 
benzoylcnoline, buffered at pH 7.4, as substrate. The Bero 
order reaotion was determined with and without the addition 
of dibucai:iLu The degree of inhibition expressed as a per 
oentage was recorded as the "dibuoaine number". 
Benzoylcholine is a relatively stable compund showing 
an absorbence maximum at 240 nm. Enzymatic aotivity is deter-
mined kinetioally (time-rate) by observing the loss of absor-
banoe as the benzoylcholine is hydrolyzed to henzoate and 
choline. -.iatively large conoentrations of the produot, 
benzoate, produce little absorbance at this wavelength. Benzoyl. 
choline is a relatively resistant to spontaneous hydrolysis 
except by the action of bacterial or fungal growth aand must 
be stored at 50 0. Excess, substrate has an 1nhibitory effect 
just as 1t does when acetylcho11ne is used to estimate true 
ohvlinesterase. Por th1s ~son. very dilute substrate con-
centrations were used. The deainllct'nn of benzoylcholin.:by 
serum cholinesterase proceeds at least 35 times faster than 
that of acetylcholine when substrate concentrations in the 
order of lO-SX'are usedo 
Human serum or plasma wasd1luted USOl~ifl MIlS phosi!io 
phate buffer, pH 7.4, and added to benzoylcholine substrate 
w1th and w1thout the addition of dibucaine as an inhibitor.'~ 
Oonstant time-rate spectrophotometric anaylsis was determined 
at 240 nm using a Gilford 2000 record1ng speotrophotometer 
w1th automatic cuvette changer, thermoregulator at 2S0 0'., and 
1 em square quartz ouvettes. Reaot1ons were observed over a 
-1-
period ot 3 minutes and a ohange in absorbance per minute with 
and without the inhibitor was determined. The dibuoaine num-
ber, that is, the peroentage of inhibition, was oaloulated 
as 100 times jl-(deorease absorbance in presenoe of dibucaine 
divided by decrease in aabsorbanoe without dibucaine)/. Total 
esterase units were arbitrarily expressed as micromols ot 
acetyloholine hydrolyzed by 1 co of serum in one hour at 370 
and were arbitrarily compared to the hydrolysis of benzoly-
choline. The total value was not a part of the study other 
than the observation that the homozygous atypicals tended to 
have lower tatal, .. a.bsorbance values than did normals. 
case Studies 
Qase 1. LR, 6-year.old whlite male. developed plJolonged 
post anesthetic apnea while undergoing a hernia repair. His 
dibucaine number was 18. The father and mother bad dibuoaine 
numbers of 61 and 72 respectively_ Five siblings bad numbers 
ot 71, 68, 71, 85. and 86. A llf.-year-old sibling had a D.N. 
a! 28. Interestingly enough this sibling bad undergone a 
hernia repair some 3 years before without inoident in which 
succinylcholine was administered. 
case 2. fL. 62-year-old female, experienced apprOXimately 
8 hours post-anesthetic apnea While having a hiatal hernia 
repaired. Her D.N., was 18. Normal siblings had dibucaine 
numbers of 68, 66, and 84, but one 61-year-old sister had a 
D.N. of 23. 
-8-
Qase:: 3. BY, 55-;rear-old femalit,~ experience4 profound 12 
hour apnea after receiving succinylcholine during the course 
of an intrAmedullary nail pinning of a fractured hip. Her D.B. 
was 25. A son and grandson&:had numbers of 68, 67, gnd 86. 
case 4. liD, Sr., 34-year-old male, experienced severe apnea 
following succinylchoine administration while having a It.ernia 
repair. His dibucaine number was 14. His children had D~.~N.·S 
of 61 and 66. 
Results 
BY' this method normal patients (homozygote. (11'11-B1U),:: 
tended to bave dibucaine numbers between 70-85% as did normals 
whose total ma;r have been somewhat low secondary to liver 
disease. Abnormal homozygotes (lla -E1a ) 'clustere4 between 16 
and 25. Heterozygotes by the dibucaine mettod were noted to 
be between 50 and 65. 
It 1s interesting to note that the parents who were 
apparently homo zygotes for the gene E1
a had total cholinesterase 
levels Significantly lower than the 0.040-0.050 Absorbance 
uni ts per minute -- of the normal range, running from 
O.025A to 0.030A per minute. It ls interesting to speculate 
on the apparent heterozygotic nature of the .arious ralatives 
studied. 
Oonclusion 
!be relationship of lnhlbitible pseudocholinesterase 
activity in serum and suxamethonium appea appears well 
-9-
defined although tbe norma,Fi function of plasJlllapselldo-
cholinesterase is poorly understood. The methods available 
for the determination of dibuca1ne 1nhibitable pseudo-
cholinesterase are reasonab~ simple and precise. Tlis 
determination should be performed on all patients who have 
had prior post-anesthetic apneic reactions themselves or 
have a family history of a similar event. 
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